Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Armstrong, Paul; Pieske, Burkert; Anstrom, Kevin; Ezekowitz, Justin; Hernandez, Adrian; Butler, Javed; Lam, Carolyn; Ponikowski, Piotr; Voors, Adriaan; Jia, Gang; McNulty, Steven; Patel, Mahesh; Roessig, Lothar; Koglin, Joerg; O'Connor, Christopher

doi:10.1056/nejmoa1915928

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Armstrong P. W., Pieske B., Anstrom K. J., Ezekowitz J., Hernandez A. F., Butler J., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.382, sa.20, ss.1883-1893, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 382 Sayı: 20
Basım Tarihi: 2020
Doi Numarası: 10.1056/nejmoa1915928
Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
Sayfa Sayıları: ss.1883-1893
Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

BackgroundThe effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.